论文部分内容阅读
本研究分析难治/复发髓系白血病行脐带间充质干细胞(UC-MSC)联合单倍体相合异基因造血干细胞(haplo-HSCT)移植的临床疗效。回顾性总结2007年1月-2013年6月完成的36例难治/复发髓系白血病患者进行UC-MSC联合haplo-HSCT移植后的资料,分析移植后细胞植入、移植物抗宿主病发生率及其严重程度和2年总生存情况。结果表明,36例患者白细胞和血小板植入时间分别为12 d及14 d,Ⅲ-Ⅳ度aGVHD发生率为13.8%,cGVHD发生率为37.5%,广泛性cGVHD仅为6.25%,2年总生存为76.9%。结论:UC-MSC联合haplo-HSCT移植对难治/复发髓系白血病患者具有良好疗效,是用于有高危因素和无全相合供者患者治疗方法之一。
This study was to analyze the clinical efficacy of umbilical cord mesenchymal stem cells (UC-MSCs) combined with haploidentical HSC transplantation in patients with refractory / relapsed myeloid leukemia. The data of UC-MSC combined with haplo-HSCT in 36 patients with refractory / recurrent myeloid leukemia completed from January 2007 to June 2013 were retrospectively reviewed. Cell engraftment and graft-versus-host disease were analyzed after transplantation Rates and their severity and 2-year overall survival. The results showed that the leukocyte and platelet transplants in 36 patients were 12 days and 14 days respectively. The incidence of grade Ⅲ-Ⅳ aGVHD was 13.8%, the incidence of cGVHD was 37.5%, the generalized cGVHD was only 6.25%, and the 2-year overall survival 76.9%. CONCLUSION: UC-MSC combined with haplo-HSCT has good curative effect in patients with refractory / recurrent myeloid leukemia and is one of the treatment options for patients with high-risk and non-full-phase partners.